Showing results (591-600 of 2,338) with videos related to
Sort By:
Pageof 234
Clinical Lung Cancer|June 14, 2011
Clinical value of assaying tumor supplied group of factor/tumor specific growth factor in patients with solitary pulmonary noduleBo Deng, Qun-You Tan, Xiao-Qing Fan, et al.Clinical Lung Cancer|June 28, 2011
Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published dataGiannis Mountzios, Vassilis Ramfidis, Evangelos Terpos, et al.Clinical Lung Cancer|July 15, 2011
Are clinical guidelines applied in routine daily practice?: a French regional survey of physicians' clinical practices in lung cancer management (EPOTRA)Sébastien Couraud, Pierre Fournel, Denis Moro-Sibilot, et al.Clinical Lung Cancer|August 6, 2011
Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspectiveJoaquim Bosch-Barrera, Nuria Quer, Joan BrunetClinical Lung Cancer|August 12, 2011
Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancerWaldo Ortuzar, Nasser Hanna, Eduardo Pennella, et al.Clinical Lung Cancer|August 12, 2011
Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigmsDavid P Carbone, Enriqueta FelipClinical Lung Cancer|September 6, 2011
Development and validation of a clinical prediction model to estimate the probability of malignancy in solitary pulmonary nodules in Chinese peopleYun Li, Ke-Zhong Chen, Jun WangClinical Lung Cancer|July 6, 2011
Comorbidity in lung cancer: important but neglected. a review of the current literatureDerek Grose, Graham Devereux, R MilroyClinical Lung Cancer|July 6, 2011
Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric studyR Charles Nichols, Soon N Huh, Randal H Henderson, et al.Clinical Lung Cancer|September 3, 2011
Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancerJustin F Klamerus, Julie R BrahmerPageof 234